Individualized Treatment for Patients With Familial Hypercholesterolemia

Hayato Tada ©, Masayuki Takamura ©, Masa-aki Kawashiri ©
Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

ABSTRACT

Familial hypercholesterolemia (FH) is one of the most common and, therefore, important inherited disorders in preventive cardiology. This disease is mainly caused by a single pathogenic mutation in the low-density lipoprotein receptor or its associated genes. Moreover, it is correlated with a high risk of cardiovascular disease. However, the phenotype severity even in this monogenic disease significantly varies. Thus, the current study aimed to describe FH and its importance and the factors (inherited and acquired) contributing to differences in phenotype severity. Different lipid-modification therapies according to these factors can lead to individualized treatments, which are also essential in the general populations.

Keywords: Hyperlipoproteinemia type II; LDL receptors; Cardiovascular diseases

INTRODUCTION

Familial hypercholesterolemia (FH) is characterized by the clinical triad of primary low-density lipoprotein (LDL) hypercholesterolemia, tendon xanthomas, and premature coronary artery disease (CAD). This disease is mainly caused by pathogenic mutations in genes. These include the LDL receptor (LDLR), apolipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDL receptor adaptor protein 1 (LDLRAP1), which are associated with LDL metabolism. Based on the number of pathogenic FH mutation, FH is classified into heterozygous FH (HeFH) with a single FH mutation and homozygous FH (HoFH) caused by mutations of both copies of FH genes. The LDL cholesterol level in HeFH is about two times higher, and that in HoFH is four times higher than that of the general population. Thus, patients with HoFH exhibit more severe phenotypes than those with HeFH. Therefore, the current understanding of the different types of FH and the importance of genetic analysis for not only their diagnosis but also further risk stratification were discussed.
FH AND DEVELOPMENT OF CORONARY ATHEROSCLEROSIS

FH was initially described as xanthomatous disease and first documented approximately 100 years ago.\(^1\) Since then, it was characterized by the clinical triad of primary LDL hypercholesterolemia, tendon xanthomas, and premature CAD. Further, in the 1970s, Brown and Goldstein discovered that it was primarily caused by genetic abnormalities in \(LDLr\).\(^1\) More recently, studies have found that it was correlated with \(LDLr\)-associated genes including \(APOB\), \(LDLRAP1\), and \(PCSK9\).\(^2,3,19-22\) Its prevalence in the general population is approximately 1 per 500 persons.\(^23\) However, another study showed that its prevalence was as high as 1 per 208 person based on genetic studies conducted in Hokuriku district in Japan.\(^24\) Based on reports published after ours, the prevalence of FH in the general population in the United States and Europe is similar.\(^25,26\) Recent meta-analyses have revealed that its prevalence rates are around 1 per 300 person in the general population, 1 per 31 among patients with CAD, and 1 per 15 among patients with premature CAD.\(^27,28\)

Interestingly, this disorder uniquely exemplifies the causal association between LDL cholesterol and CAD because of the following facts: 1) patients with FH who have hypercholesterolemia since birth have a significantly higher risk for CAD than the general populations and their siblings who do not have mutations,\(^29\) 2) the use of LDL cholesterol-lowering method can reduce the risk of CAD,\(^30\) 3) The most frequent cause of death at earlier ages compared with non-FH among patients with untreated FH is CAD (Fig. 1),\(^1\) and 4) FH accounts for 3%–8% of all patients with acute coronary syndrome.\(^31-33\)

In 1970, Brown and Goldstein described the role of \(LDLr\) in LDL metabolism, and results showed that FH could be caused by a defect in this gene. Since its discovery, along with the development and standardization of genetic analysis, several different pathogenic mutations have been identified,\(^34-36\) which include those in the \(APOB\) and \(PCSK9\) genes. Based on this concept, only one monogenic mutation causes the critical phenotype. Thus, both cascade screening and the assessment of segregation pattern are important. However, in a substantial proportion of patients with FH, no deleterious mutation in such genes has been found.\(^37,38\) Therefore, researchers have been assessing one or more novel genes associated with this disorder via comprehensive genetic analyses, including exome sequencing.\(^39\) However, there was no novel gene compatible with the concept of the monogenic type of FH, which

**Fig. 1.** Cause of death and average life span of patients with HeFH.
(A) Cause of death. (B) Average life span.
HeFH, heterozygous familial hypercholesterolemia; CAD, coronary artery disease.
is the standard type of FH, and the presence of pathogenic mutation in FH-gene has been associated with a higher risk of CAD, independent of LDL cholesterol level. Moreover, the presence of pathogenic mutation in FH-gene increased the risk of developing CAD in people other than those with FH, which include those with a family history of premature CAD/FH and Achilles tendon thickness. Collectively, these data indicate that the identification of monogenic FH could be quite useful for not only diagnosis but also further risk stratification.

**PHENOTYPIC VARIATIONS OF FH AND SEVERE FH**

FH is associated with an extremely high risk for CAD. However, there are substantial phenotypic variations in this simple familiar disorder. Some patients with FH present with severe CAD during early life. Meanwhile, other patients do not. In fact, there are several different types of clinical criteria for FH worldwide, which include the Dutch Lipid Clinic Network, Simon Broome, and Japan Atherosclerosis Society. However, none of these specifically defined severe FH. Under these circumstances, the International Atherosclerosis Society defines severe familial hypercholesterolemia and the implications for clinical management in 2016. Several factors can contribute to such phenotypic variations, or severity. These include the classical risk factors of coronary atherosclerosis, such as hypertension, diabetes, and smoking, which are not specific to FH. By contrast, the factors specific to FH associated with a more severe phenotype, such as Achilles tendon thickness and the presence of pathogenic mutation in FH-gene, should be identified.

**PHENOTYPIC VARIATIONS OF FH**

1. **Achilles tendon thickness**

   There are several clinical factors correlated with the phenotypic severity of FH. For example, Achilles tendon thickness, which is quite a specific physical finding of FH, is associated with worse clinical outcomes among patients with extremely elevated LDL cholesterol levels. This phenomenon may be attributed to the fact that Achilles tendon thickness reflects not only the state of FH but also exposure to more elevated LDL cholesterol levels with inflammatory properties. Moreover, it is positively associated with aging only among patients with FH, and the association between Achilles tendon thickness and cholesterol year score is stronger than that of Achilles tendon thickness and simple aging. Collectively, these data indicate that patients with FH should be diagnosed before the occurrence of Achilles tendon thickening, even though this is one of the major diagnostic criteria of the disease. In addition to these specific physical findings, we showed that the presence of pathogenic mutation in FH-gene (e.g., LDLR and PCSK9) was significantly associated with a higher risk for CAD, independent of other conventional risk factors (Fig. 2). This likely reflects the fact that patients with FH mutation have true FH, and their LDL cholesterol level have been elevated since the fetal period.

2. **Assessment of coronary and carotid plaque in FH**

   Currently, we can assess the plaque burden of coronary artery invasively and less invasively. For example, intravascular ultrasonography (IVUS) has been a useful tool for assessing coronary artery plaque burden for not only patients with FH but also the non-FH general populations. A larger plaque burden has been associated with worse clinical outcomes. Thus, the assessment of plaque burden quantitatively may be a useful marker for risk stratification in
patients with FH. Moreover, we can assess coronary plaque burden via computed tomography (CT) scan, which is a less invasive procedure. Coronary plaque burden assessed with CT scan were significantly associated with future cardiovascular events in FH.

In addition to the assessments of coronary plaque burden, CT scan can be performed to assess coronary and aortic calcification quantitatively, which is also associated with future cardiovascular events. Moreover, we can now assess other important characteristics of coronary plaque, such as the presence of lipid-rich plaque and thin-cap fibroatheroma, using optical coherence tomography. Both of them have been associated with worse clinical outcomes.

By contrast, we can assess their state of atherosclerosis non-invasively via carotid ultrasonography. It is quite helpful for this purpose because 1) it can be used to assess plaque burden in pediatric patients with FH, 2) plaque burden can be evaluated quantitatively, and 3) carotid plaque burden is associated with future cardiovascular events in patients with FH. Using these modalities, we showed that carotid plaque may start to develop at the age of 17 years in men and 26 years in women. Hence, individuals with FH must be diagnosed before those ages.

**FACTORs CONTRIBUTING TO THE PHENOTYpic VARIATIONS OF FH**

1. **Conventional and FH-specific factors associated with atherosclerosis**

   Other studies and ours have revealed that conventional risk factors for coronary atherosclerosis, such as hypertension, diabetes, and smoking, are also associated with disease severity even among patients with FH. Some reports have shown that lipoprotein (a) (Lp[a]) can exacerbate the phenotype. Notably, patients with FH have elevated Lp(a) levels, indicating that LDLR may be involved in the catabolism of Lp(a). All these factors are not specific to FH but are applicable to the general populations.

2. **Timing of the initial therapy (cascade vs. proband)**

   With consideration of FH phenotype severity, the timing of diagnosis is quite important, and this might also be applicable in other cardiometabolic inherited diseases. For example,
almost all patients with pediatric HeFH are asymptomatic, except for those with hyper-LDL cholesterol. Meanwhile, adult patients with HeFH are gradually developing carotid and coronary atherosclerosis (Fig. 3).\textsuperscript{59,60} Moreover, early diagnosis and LDL-lowering therapy at childhood can prevent atherosclerotic cardiovascular disease (ASCVD) events.\textsuperscript{68} In addition, in our study, we managed brothers with compound heterozygous FH. That is, the older brother who was initially treated at the age of 23 years exhibited repeated coronary events. Meanwhile, the younger brother who has been receiving treatment since the age of 15 years had been event-free for a long period, despite having similar LDL cholesterol levels caused by the same mutations (NM\_000527.4 [LDLR]\_c.2054C>T [p.Pro685Leu]/ NM\_000527.4 [LDLR]\_c.2431A>T [p.Lys811Ter]) (Fig. 4).\textsuperscript{69} The phenotypic difference between them clearly indicate that early intervention for LDL cholesterol can be quite beneficial even for extremely worse cases. In fact, we have shown that Achilles tendon thickness in HeFH was significantly associated with age.\textsuperscript{41} In addition, it is correlated with phenotypic severity.\textsuperscript{41} Accordingly, diagnosing patients with FH prior to Achilles tendon thickening may be quite beneficial to prevent ASCVD events.

In order to identify patients with FH at early phase of this disorder, there are two major methods that can effectively identify patients with FH. First is the universal screening at a certain age, which is a proposed screening method for FH.\textsuperscript{70,71} Second is the cascade screening for FH, which has been recommended by several organizations worldwide.\textsuperscript{72,73} In countries

---

**Fig. 3.** Coronary and carotid plaque score assessed via computed tomography scan or carotid ultrasonography. Upper panel indicates coronary plaque score. The X-axis represents age and the Y-axis represents coronary plaque score. The blue section indicates men; the red section, women. Lower panel indicates carotid plaque score. The X-axis represents age and the Y-axis represents carotid plaque score. The blue section indicates men; the red section, women.
where dedicated cascade screening programs have been implemented, the number of patients with FH is significantly higher. For example, about 71% and 43% of patients were diagnosed with FH in the Netherlands and Norway, respectively. In any case, we strongly recommend to identify as many patients with FH. Then, early treatment should be started if possible.

3. Cholesterol year score

In recent years, the accumulation of exposure to cholesterol for a long period has been proposed to contribute the development of coronary atherosclerosis, and this considered an important concept. This is an idea based on the fact that LDL cholesterol is the causal factor for coronary atherosclerosis, and this concept is likely to explain the development of coronary atherosclerosis in HeFH and HoFH, including attenuation by LDL-lowering therapies. Typically, cholesterol-year-score is calculated as: LDL Cholesterol Max × (Age at Diagnosis/Statin Initiation) + LDL Cholesterol at Inclusion × (Age at Inclusion – Age at
Diagnosis/Statin Initiation). In fact, we have shown that a cholesterol year score representing the accumulation of exposure to LDL cholesterol in HeFH is significantly associated with major cardiovascular events beyond their cross-sectional LDL cholesterol levels. In addition, it was significantly correlated with Achilles tendon thickness in HeFH, which was one of the established clinical signs of severe FH. Collectively, these data indicated that we need to the degree and duration of exposure to elevated LDL cholesterol.

4. Genetic backgrounds of FH (LDLR, PCSK9 E32K)
About 2,000 different types of mutations causes FH in LDLR alone. Even in Japan, we have shown that at least 132 different pathogenic mutations exist, and it is likely that there are several region-specific and/or private mutations across the country (Fig. 5) and worldwide. Based on the abovementioned information, the presence of pathogenic mutation in FH-gene (LDLR or PCSK9) is associated with a higher risk for CAD. However, accumulating evidence has shown differences in the effect of mutations (and their phenotypes) on LDL cholesterol levels among the different types of FH mutations. For example, the LDL cholesterol level of patients with HeFH caused by E32K (PCSK9) was lower than that in patients with HeFH caused by K811X (LDLR) (Fig. 6). Moreover, some studies have shown that there are significant differences in phenotypes (LDL cholesterol and coronary atherosclerosis) among the different types of mutations in LDLR, such as missense mutations and loss-of-function mutations, including nonsense, frameshift, splice cite, and large insertion/deletion mutations. Thus, information regarding the pathogenicity of the genetic variations in FH must be further collected, and they can be classified according to their effects on LDL cholesterol and CAD.

Fig. 5. Pathogenic mutations in the LDLR gene found in Japanese patients with familial hypercholesterolemia. The left pie chart shows the total mutation distribution. The right upper pie chart indicates the mutation distribution found in Kanazawa University. The right lower pie chart depicts the mutation distribution found in the National Cerebral and Cardiovascular Center.

LDLR, low-density lipoprotein receptor
5. Monogenic, polygenic, and oligogenic FH

In addition to the so-called FH mutation, there are other classifications among patients with FH according to genetic backgrounds. One is monogenic FH, which is a conventional concept in which one rare deleterious pathogenic mutation causes an FH phenotype. However, Talmud et al. have discussed about polygenic FH, which is another interesting concept in which multiple common genetic variations can mimic FH phenotype. There may be substantial proportions of such patients simply because some individuals have millions of common genetic variations. However, their phenotypes are milder than those of the typical monogenic FH. By contrast, at least a portion of patients with monogenic FH also have rare and deleterious mutation(s) in the LDL-related genes, such as ATP-binding cassette sub-family G member 5 (ABCG5) and ATP-binding cassette sub-family G member 8 (ABCG8), leading to the exacerbation of their phenotype (Fig. 7). This is referred to as oligogenic FH. In fact, oligogenic FH is an unique status accompanied by mutations in related genes along with conventional FH gene mutations. ABCG5 and ABCG8 are cause sitosterolemia, which is a recessive disorder. The effect size of ABCG5 mutation may be smaller than that of LDLR mutation. Moreover, a single rare mutation in both genes can increase LDL cholesterol levels and the risk of CAD. Notably, the development of CAD can be explained by the high LDL cholesterol levels as they are linearly correlated.

6. Homozygous FH and its phenocopies

Homozygous FH is the most severe FH phenotype. Further, it is characterized by an extremely elevated LDL cholesterol level (>500 mg/dL), cutaneous xanthomas since childhood, premature CAD during childhood, and supravalvular aortic stenosis. Typically, homozygous FH refers to double pathogenic mutations in the FH genes (LDLR, PCSK9, APOB, or LDLRAP1). The severity of this condition can be assessed based on genes and/or mutation types. For example, the phenotypes of homozygous FH caused by loss-of-function mutations in LDLR are more severe than those caused by missense mutations in LDLR, PCSK9, or APOB.
addition, homozygous FH caused by \textit{LDLRAP1} mutations (so-called ARH) is characterized by a milder phenotype, probably because the function of their \textit{LDLR}, particularly in the clearance of remnant lipoproteins, is not completely impaired. Thus, based on these findings, the genotypes of homozygous FH is helpful for not only diagnosis but also risk stratification.

Moreover, sitosterolemia is an important differential diagnosis of homozygous FH. This condition is caused by double pathogenic mutations in \textit{ABCG5} or \textit{ABCG8} and is extremely rare. However, the prevalence of sitosterolemia has been significantly higher than previously expected based on the prevalence of loss-of-function mutation in the general population in public database (gnomAD). Occasionally, HoFH is challenging to differentiate from sitosterolemia because both conditions have similar symptoms. These include elevated LDL cholesterol levels, cutaneous xanthomas since childhood, and premature CAD in childhood. We have managed worse cases of sitosterolemia with premature CAD, a case of a young lady (aged 25 years old) with myocardial infarction, and a boy (aged 15 years old) with ischemic heart failure. Both patients had cutaneous xanthomas and Achilles tendon thickness similar to HoFH. Notably, the prognosis and standard therapy for sitosterolemia differ from those of HoFH. For example, ezetimibe, rather than statins, are strongly recommended. Meanwhile, dietary counseling is quite effective in reducing LDL cholesterol levels in sitosterolemia. Moreover, dietary counseling has almost no beneficial effect on HoFH. Accordingly, an accurate diagnosis which include differentiating HoFH from sitosterolemia, is important.

7. Common genetic variations associated with coronary atherosclerosis

Do common genetic variations have any effects on their phenotypes in FH? The answer is probably yes. Common genetic variations are associated with coronary atherosclerosis in the general populations. In particular, polygenic risk score (PRS) comprising multiple common genetic variations are attracting significant attention to date. Fahed et al. have shown that
independent of other traditional risk factors, such PRS is also associated with CAD among patients with FH. Notably, the most common genetic variations included in this score are associated with hypertension, diabetes, inflammation, and other unknown factors, but not with lipid levels. Accordingly, assessing such risk caused by common genetic variations are useful for not only the general populations but also patients with FH regardless of genetic status.

PRINCIPLES OF INDIVIDUALIZED TREATMENT FOR PATIENTS WITH FH

As stated above, we need to identify patients with FH very early, ideally, before their Achilles tendon becomes thick, and then start to treat them. Secondly, we need to clarify the genetic backgrounds not only for FH-gene, but also other genes associated with CAD and lipids, including common genetic variations. These information can tell us clear diagnosis of them as well as responsiveness to lipid-lowering therapy. Thirdly, we need to assess phenotypic severity, including coronary and carotid atherosclerosis. Finally, we need to decide the intensity of therapies based on all information. The most intensive therapies, including LDL apheresis and PCSK9 inhibitor would be needed when patients diagnosed late who have high risk genetic variants and exhibit coronary and carotid artery stenoses.

CONCLUSION

FH should be diagnosed as early as possible. Then, patients must receive individualized treatment based on other clinical risk factors (FH-specific or not) and genetic backgrounds (rare and common). As FH is one of the most common cardio metabolic disorders, a full understanding of its associated factors will help improve prognosis, thereby reducing the burden of cardiovascular disease worldwide.

ACKNOWLEDGEMENTS

We would like to express special thanks to Ms. Yoko Iwauchi, Ms. Kazuko Honda, and Mr. Sachio Yamamoto (staffs of Kanazawa University) for their assistance.

REFERENCES

1. Mabuchi H. Half a century tales of familial hypercholesterolemia (FH) in Japan. J Atheroscler Thromb 2017;24:189-207.
2. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007;4:214-225.
3. Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb 2021;28:665-678.
4. Foody JM, Vishwanath B. Familial hypercholesterolemia/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity. J Clin Lipidol 2016;10:970-986.
5. Santos RD. Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician? Curr Opin Lipidol 2017;28:130-135.
PUBMED | CROSSREF

6. Bourbon M, Alves AC, Alonso R, Mata N, Aguilar P, Padró T, et al. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: the SAFEHEART registry. Atherosclerosis 2017;262:8-43.
PUBMED | CROSSREF

7. Di Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: a complex genetic disease with variable phenotypes. Eur J Med Genet 2020;63:103831.
PUBMED | CROSSREF

8. Gagné C, Gaudet D, Bruckert E Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-2475.
PUBMED | CROSSREF

9. Yamamoto A, Harada-Shiba M, Endo M, Kusakabe N, Tanioka T, Kato H, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis 2006;186:126-131.
PUBMED | CROSSREF

10. Gotto AM Jr, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. Nat Rev Cardiol 2013;10:560-570.
PUBMED | CROSSREF

11. Santos RD, Stein EA, Hovingh GK, Blom DJ, Soran H, Watts GF, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020;75:565-574.
PUBMED | CROSSREF

12. Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, et al. Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia. J Atheroscler Thromb 2017;24:402-411.
PUBMED | CROSSREF

13. Nohara A, Otsubo Y, Yanagi K, Yoshida M, Ikewaki K, Harada-Shiba M, et al. Safety and efficacy of lomitapide in Japanese patients with homozygous familial hypercholesterolemia (HoFH): results from the AEGIR-733-301 long-term extension study. J Atheroscler Thromb 2019;26:368-377.
PUBMED | CROSSREF

14. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ES, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med 2020;383:2307-2319.
PUBMED | CROSSREF

15. Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther 2021;15:1955-1963.
PUBMED | CROSSREF

16. Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA. Challenges of precision medicine for atherosclerotic cardiovascular disease based on human genome information. J Atheroscler Thromb 2021;28:305-313.
PUBMED | CROSSREF

17. Fagge CH. Xanthomatous disease of the skin. I. General xanthelasma of vitiligoides. Trans Pathol Soc Lond 1873;24:242-250.

18. Thannhauser SJ, Magendanz H. The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med 1938;11:1162.
CROSSREF

19. Hori M, Takahashi A, Son C, Ogura M, Harada-Shiba M. The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln). J Clin Lipidol 2020;14:482-486.
PUBMED | CROSSREF

20. Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 2003;88:2541-2547.
PUBMED | CROSSREF

21. Tada H, Kawashiri MA, Ikewaki K, Terao Y, Noguchi T, Nakanishi C, et al. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 2012;5:35-41.
PUBMED | CROSSREF

22. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-156.
PUBMED | CROSSREF

https://e-jla.org

https://doi.org/10.12997/jla.2022.11.1.39
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York (NY): McGraw-Hill; 2001. p.2863e913.

Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 2011;214:404-407.

Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016;37:1384-1394.

de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES). Circulation 2016;133:1067-1072.

Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016;37:1384-1394.

de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES). Circulation 2016;133:1067-1072.

Benn M, Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016;37:1384-1394.

de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES). Circulation 2016;133:1067-1072.
40. Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016;67:2578-2589.

41. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. Eur Heart J 2017;38:1573-1579.

42. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolaemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-420.

43. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-896.

44. Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb 2018;25:751-770.

45. Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol 2016;4:850-861.

46. Tada H, Okada H, Nomura A, Usui S, Sakata K, Nohara A, et al. Clinical diagnostic criteria of familial hypercholesterolemia - A comparison of the Japan Atherosclerosis Society and Dutch lipid clinic network criteria. Circ J 2021;85:891-897.

47. Tada H, Okada H, Nomura A, Nohara A, Usui S, Sakata K, et al. A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis. Pract Lab Med 2020;22:e00180.

48. Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri MA, et al. Achilles tendon thickness assessed by X-ray predicting a pathogenic mutation in familial hypercholesterolemia gene. J Atheroscler Thromb. Forthcoming 2021.

49. Tada H, Okada H, Nohara A, Yamagishi M, Takamura M, Kawashiri MA. Effect of cumulative exposure to low-density lipoprotein-cholesterol on cardiovascular events in patients with familial hypercholesterolemia. Circ J 2021;85:2073-2078.

50. de Gennes JL, Daffos F, Dairou F, Forestier F, Capella-Pavlosky M, Truffert J, et al. Direct fetal blood examination for prenatal diagnosis of homozygous familial hypercholesterolemia. Arteriosclerosis 1985;5:440-442.

51. Daida H, Dohi T, Fukushima Y, Ohmura H, Miyauchi K. The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy: insights from IVUS trials. J Atheroscler Thromb 2019;26:592-600.

52. Maurovich-Horvat P, Ferencik M, Voros S, Merkely B, Hoffmann U. Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 2014;11:390-402.

53. Pérez de Isla L, Alonso R, Gómez de Diego JJ, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, et al. Coronary plaque burden, plaque characterization and their prognostic implications in familial hypercholesterolemia: a computed tomographic angiography study. Atherosclerosis 2021;317:52-58.

54. Okada H, Tada H, Hayashi K, Kawashima H, Takata T, Sakata K, et al. Aortic root calcification score as an independent factor for predicting major adverse cardiac events in familial hypercholesterolemia. J Atheroscler Thromb 2018;25:634-642.

55. Miname MH, Bittencourt MS, Pereira AC, Jannes CE, Krieger IE, Nasir K, et al. Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia. Eur Heart J Cardiovasc Imaging 2020;21:251-257.
56. Gallo A, Pérez de Isla L, Charrière S, Vimont A, Alonso R, Muñiz-Grijalvo O, et al. The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia. JACC Cardiovasc Imaging 2021;14:2414-2424.

57. Liu Z, Peng J, Wang S, Jiang T, Zhang W, Zhang C, et al. Percutaneous coronary intervention for a Chinese familial hypercholesterolemia homozygous under the guidance of optical coherence tomography. Atheroscler Suppl 2019;36:19-23.

58. Katamine M, Minami Y, Hashimoto T, Ako J. Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease. Pract Lab Med 2021;24:e00202.

59. Tada H, Kawashiri MA, Okada H, Nakahashi T, Sakata K, Nohara A, et al. Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia. Am J Cardiol 2017;120:1955-1960.

60. Tada H, Kawashiri MA, Okada H, Teramoto R, Konno T, Yoshimuta T, et al. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol 2015;115:724-729.

61. Tada H, Kawashiri MA, Nohara A, Inazu A, Mabuchi H, Yamagishi M. Assessment of arterial stiffness in patients with familial hypercholesterolemia. J Clin Lipidol 2018;12:397-402.e2.

62. Tada H, Kawashiri MA, Nohara A, Sakata K, Inazu A, Mabuchi H, et al. Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Clin Chim Acta 2018;482:120-123.

63. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation 2015;132:2167-2192.

64. Li S, Wu NQ, Zhu CG, Zhang Y, Guo YL, Gao Y, et al. Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease. Atherosclerosis 2017;260:67-74.

65. Vuorio A, Watts GF, Schneider WJ, Tsimikas S, Kovanen PT. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med 2020;287:2-18.

66. Tada H, Kawashiri MA, Yoshida T, Teramoto R, Nohara A, Konno T, et al. Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin/kexin Type 9 (PCSK9) gain-of-function mutations. Circ J 2016;80:512-518.

67. Tada H, Takamura M, Kawashiri MA. Familial hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag 2021;17:59-67.

68. Luirink IK, Wiegman A, Zuidema J, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019;381:1547-1556.

69. Tada H, Usui S, Sakata K, Takamura M, Kawashiri MA. Low-density lipoprotein cholesterol level cannot be too low: considerations from clinical trials, human genetics, and biology. J Atheroscler Thromb 2020;27:489-498.

70. Lozano P, Henriksen NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, et al. Lipid screening in childhood and adolescence for detection of familial hypercholesterolemia: Evidence report and systematic review for the US Preventive Services Task Force. JAMA 2016;316:645-655.

71. Grossel U, Kovac J, Sustar U, Mlinaric M, Fras Z, Podkrajsek KT, et al. Universal screening for familial hypercholesterolemia in children: the Slovenian model and literature review. Atherosclerosis 2018;277:383-391.

72. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015;36:2425-2437.
73. Tada H, Okada H, Nomura A, Nohara A, Yamagishi M, Takamura M, et al. Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. J Clin Lipidol 2021;15:358-365.

74. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HG, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-3490a.

75. Brautbar A, Leary E, Rasmussen K, Wilson DP, Steiner RD, Virani S. Genetics of familial hypercholesterolemia. Curr Atheroscler Rep 2015;17:491.

76. Kim H, Lee CJ, Pak H, Kim DI, Rhee MY, Lee BK, et al. GENetic characteristics and REsponse to lipid-lowering therapy in familial hypercholesterolemia: GENRE-FH study. Sci Rep 2020;10:19336.

77. Lee SH. Characteristics and vascular complications of familial hypercholesterolemia in Korea. J Atheroscler Thromb 2016;23:532-538.

78. Santos PC, Pereira AC. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. Pharmacogenomics 2015;16:1743-1750.

79. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013;381:1293-1301.

80. Kwon M, Han SM, Kim DI, Rhee MY, Lee BK, Ahn YK, et al. Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis. Atherosclerosis 2015;242:8-12.

81. Wang J, Dron JS, Ban MR, Robinson JF, McIntyre AD, Alazzam M, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol 2016;36:2439-2445.

82. Mariano C, Alves AC, Medeiros AM, Chora JR, Antunes M, Futema M, et al. The familial hypercholesterolaemia phenotype: monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes. Clin Genet 2020;97:457-466.

83. Tada H, Kawashiri MA, Nomura A, Teramoto R, Hosomichi K, Nohara A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol 2018;12:1436-1444.

84. Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, et al. Diagnosis and management of sitosterolemia 2021. J Atheroscler Thromb 2021;28:791-801.

85. Nomura A, Emdin CA, Won HH, Peloso GM, Natarajan P, Ardissino D, et al. Heterozygous ABCG5 gene deficiency and risk of coronary artery disease. Circ Genom Precis Med 2020;13:417-423.

86. Tada H, Kawashiri MA, Tanaka A, Nakano T, Nakajima K, Inoue T, et al. Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. Eur J Clin Invest 2012;42:1094-1099.

87. Tada H, Kawashiri MA, Nohara A, Inazu A, Kobayashi J, Mabuchi H, et al. Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies. J Atheroscler Thromb 2015;22:3-9.

88. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020;581:434-443.

89. Kawamura R, Saiki H, Tada H, Hata A. Acute myocardial infarction in a 25-year-old woman with sitosterolemia. J Clin Lipidol 2018;12:246-249.

90. Tanaka H, Watanabe Y, Hirano S, Tada H, Nomura A, Kawashiri MA, et al. Sitosterolemia exhibiting severe hypercholesterolemia with tendon xanthomas due to compound heterozygous ABCG5 gene mutations treated with ezetimibe and alirocumab. Intern Med 2020;59:3033-3037.
91. Yamada Y, Sugi K, Gatate Y, Senbonmatsu T, Inoue I, Fukushima K, et al. Premature acute myocardial infarction in a young patient with sitosterolemia. CJC Open 2021;3:1085-1088.
PUBMED | CROSSREF

92. Tada H, Nohara A, Inazu A, Sakuma N, Mabuchi H, Kawashiri MA. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb 2018;25:783-789.
PUBMED | CROSSREF

93. Tada H, Melander O, Louie JZ, Catanese JJ, Rowland CM, Devlin JJ, et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur Heart J 2016;37:561-567.
PUBMED | CROSSREF

94. Fahed AC, Wang M, Homburger JR, Patel AP, Bick AG, Neben CL, et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun 2020;11:3635.
PUBMED | CROSSREF